CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Income Statement [Abstract]
Net revenues	$ 52,125	$ 34,880	$ 177,026
Cost of revenues	18,238	11,664	55,609
Gross profit	33,887	23,216	121,417
Operating costs and expenses:
Research, development and clinical trials	11,104	9,411	38,103
Sales and marketing	18,135	14,756	63,528
General and administrative	17,325	12,422	59,114
Total operating costs and expenses	46,564	36,589	160,745
Operating loss	(12,677)	(13,373)	(39,328)
Financial expenses, net	4,853	2,446	9,169
Loss before income taxes	(17,530)	(15,819)	(48,497)
Income taxes	3,194	2,226	13,165
Net loss	$ (20,724)	$ (18,045)	$ (61,662)
Basic and diluted net loss per ordinary share	$ (0.23)	$ (0.21)	$ (0.70)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	89,985,612	87,452,983	88,546,719